vs

Side-by-side financial comparison of CS Disco, Inc. (LAW) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $41.9M, roughly 1.8× CS Disco, Inc.). On growth, CS Disco, Inc. posted the faster year-over-year revenue change (14.3% vs -36.9%). Over the past eight quarters, CS Disco, Inc.'s revenue compounded faster (7.9% CAGR vs -34.4%).

CS Disco, Inc. is a leading legal technology provider that develops cloud-based software solutions for legal practitioners. Its core offerings include e-discovery, document review, case management, and legal workflow automation tools, serving law firms, corporate legal teams, and government legal departments primarily in North America.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

LAW vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.8× larger
MED
$75.1M
$41.9M
LAW
Growing faster (revenue YoY)
LAW
LAW
+51.2% gap
LAW
14.3%
-36.9%
MED
Faster 2-yr revenue CAGR
LAW
LAW
Annualised
LAW
7.9%
-34.4%
MED

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LAW
LAW
MED
MED
Revenue
$41.9M
$75.1M
Net Profit
$-9.6M
Gross Margin
74.2%
69.4%
Operating Margin
1.7%
-10.4%
Net Margin
-23.0%
Revenue YoY
14.3%
-36.9%
Net Profit YoY
15.6%
EPS (diluted)
$-0.15
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAW
LAW
MED
MED
Q1 26
$41.9M
Q4 25
$41.2M
$75.1M
Q3 25
$40.9M
$89.4M
Q2 25
$38.1M
$105.6M
Q1 25
$36.7M
$115.7M
Q4 24
$37.0M
$119.0M
Q3 24
$36.3M
$140.2M
Q2 24
$36.0M
$168.6M
Net Profit
LAW
LAW
MED
MED
Q1 26
$-9.6M
Q4 25
$-8.5M
Q3 25
$-13.7M
$-2.3M
Q2 25
$-10.8M
$2.5M
Q1 25
$-11.4M
$-772.0K
Q4 24
$-25.2M
Q3 24
$-9.2M
$1.1M
Q2 24
$-10.8M
$-8.2M
Gross Margin
LAW
LAW
MED
MED
Q1 26
74.2%
Q4 25
75.1%
69.4%
Q3 25
75.5%
69.5%
Q2 25
74.6%
72.6%
Q1 25
74.1%
72.8%
Q4 24
74.2%
74.1%
Q3 24
73.1%
75.4%
Q2 24
74.2%
73.2%
Operating Margin
LAW
LAW
MED
MED
Q1 26
1.7%
Q4 25
-22.4%
-10.4%
Q3 25
-35.3%
-4.6%
Q2 25
-31.0%
-1.0%
Q1 25
-34.4%
-1.1%
Q4 24
-70.6%
0.6%
Q3 24
-30.0%
1.5%
Q2 24
-34.4%
-4.7%
Net Margin
LAW
LAW
MED
MED
Q1 26
-23.0%
Q4 25
-20.7%
Q3 25
-33.4%
-2.5%
Q2 25
-28.4%
2.3%
Q1 25
-31.1%
-0.7%
Q4 24
-68.1%
Q3 24
-25.3%
0.8%
Q2 24
-30.1%
-4.8%
EPS (diluted)
LAW
LAW
MED
MED
Q1 26
$-0.15
Q4 25
$-0.13
$-1.64
Q3 25
$-0.22
$-0.21
Q2 25
$-0.18
$0.22
Q1 25
$-0.19
$-0.07
Q4 24
$-0.43
$0.08
Q3 24
$-0.15
$0.10
Q2 24
$-0.18
$-0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAW
LAW
MED
MED
Cash + ST InvestmentsLiquidity on hand
$103.0M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$123.9M
$198.9M
Total Assets
$162.4M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAW
LAW
MED
MED
Q1 26
$103.0M
Q4 25
$114.6M
$167.3M
Q3 25
$113.5M
$173.5M
Q2 25
$114.5M
$162.7M
Q1 25
$118.8M
$164.6M
Q4 24
$129.1M
$162.3M
Q3 24
$126.8M
$170.0M
Q2 24
$130.0M
$163.5M
Stockholders' Equity
LAW
LAW
MED
MED
Q1 26
$123.9M
Q4 25
$128.1M
$198.9M
Q3 25
$130.6M
$214.7M
Q2 25
$137.9M
$216.0M
Q1 25
$142.2M
$211.0M
Q4 24
$147.5M
$210.1M
Q3 24
$167.3M
$207.3M
Q2 24
$170.9M
$205.3M
Total Assets
LAW
LAW
MED
MED
Q1 26
$162.4M
Q4 25
$173.6M
$248.0M
Q3 25
$174.8M
$268.2M
Q2 25
$164.9M
$269.3M
Q1 25
$168.0M
$280.0M
Q4 24
$180.3M
$284.2M
Q3 24
$194.4M
$291.2M
Q2 24
$198.0M
$293.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAW
LAW
MED
MED
Operating Cash FlowLast quarter
$-11.7M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAW
LAW
MED
MED
Q1 26
$-11.7M
Q4 25
$762.0K
$-5.3M
Q3 25
$-979.0K
$12.1M
Q2 25
$-4.2M
$-3.4M
Q1 25
$-10.5M
$3.4M
Q4 24
$2.1M
$-4.9M
Q3 24
$-2.9M
$9.1M
Q2 24
$-650.0K
$13.1M
Free Cash Flow
LAW
LAW
MED
MED
Q1 26
Q4 25
$255.0K
$-6.6M
Q3 25
$-2.0M
$10.8M
Q2 25
$-5.2M
$-4.8M
Q1 25
$-11.0M
$1.9M
Q4 24
$1.5M
$-7.2M
Q3 24
$-3.7M
$7.7M
Q2 24
$-1.3M
$11.1M
FCF Margin
LAW
LAW
MED
MED
Q1 26
Q4 25
0.6%
-8.8%
Q3 25
-5.0%
12.0%
Q2 25
-13.6%
-4.5%
Q1 25
-30.1%
1.6%
Q4 24
4.1%
-6.1%
Q3 24
-10.3%
5.5%
Q2 24
-3.6%
6.6%
Capex Intensity
LAW
LAW
MED
MED
Q1 26
Q4 25
1.2%
1.8%
Q3 25
2.6%
1.5%
Q2 25
2.5%
1.3%
Q1 25
1.4%
1.3%
Q4 24
1.5%
1.9%
Q3 24
2.4%
1.0%
Q2 24
1.8%
1.1%
Cash Conversion
LAW
LAW
MED
MED
Q1 26
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons